Skip to main content
SpringerLink
Log in

Aktinische Keratosen

Actinic keratoses

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Aktinische Keratosen (AKs) nehmen mittlerweile einen großen Stellenwert in unserem dermatologischen Alltag ein. Aufgrund der immer älter werdenden Gesellschaft ist auch weiterhin von einer Zunahme der AK-Patienten in Klinik und Praxis auszugehen. Um die Entwicklung eines Plattenepithelkarzinoms zu vermeiden, sollte frühzeitig eine Behandlung erfolgen. Zahlreiche Therapieoptionen stehen hierfür aktuell zur Verfügung. Neben läsionsgerichteten Behandlungen für isolierte AKs gibt es auch gute Therapiemöglichkeiten bei Vorliegen einer Feldkanzerisierung. Welches Behandlungsverfahren letztlich angewendet wird, sollte individuell von dem Befund sowie den Bedürfnissen des Patienten abhängig gemacht werden.

Abstract

Actinic keratosis (AK) is a very common skin diagnosis in office-based dermatology. Due to the demographic changes with increasing numbers of elderly people, the proportion of patients with AK is expected rise. In order to avoid progression into squamous cell carcinoma, early treatment is recommended. Numerous treatment options are currently available for this purpose. In addition to targeted therapies for isolated AK many field-directed treatment modalities are available. However, the treatment option that is finally chosen depends on a variety of factors (e.g., age of the patient, the extent of the clinical findings) and the patient’s needs and therefore has to be customized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Schaefer I, Augustin M, Spehr C et al (2014) Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. J Eur Acad Dermatol Venereol 28:309–313

    Article  CAS  PubMed  Google Scholar 

  2. Strunk T, Szeimies RM (2014) Aktinische Keratosen. Pathogenese, Klinik und moderne Therapieoptionen. Hautarzt 65:241–252

    Article  CAS  PubMed  Google Scholar 

  3. Memon AA, Tomenson JA, Bothwell J et al (2000) Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 142:1154–1159

    Article  CAS  PubMed  Google Scholar 

  4. Chetty P, Choi F, Mitchell T et al (2015) Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther 5:19–35

    Article  Google Scholar 

  5. Schmitt J, Seidler A, Diepgen TL et al (2011) Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 164:291–307

    Article  CAS  PubMed  Google Scholar 

  6. Oldenburg M, Kuechmeister B, Ohnemus U et al (2013) Actinic keratosis among seafarers. Arch Dermatol Res 305:787–796

    Article  CAS  PubMed  Google Scholar 

  7. Miligi L, Benvenuti A, Legittimo P et al (2013) Solar ultraviolet radiation risk in outdoor workers: a specific project of Tuscany region (Italy). Epidemiol Prev 37:51–59

    PubMed  Google Scholar 

  8. Trakatelli M, Barkitzi K, Apap C (2016) Skin cancer risk in outdoor workers: a European multicenter case-control study. J Eur Acad Dermatol Venereol 30(Suppl 3):5–11

    Article  PubMed  Google Scholar 

  9. Diepgen TL, Brandenburg S, Aberer W et al (2014) Skin cancer induced by natural UV-radiation as an occupational disease-requirements for its notification and recognition. J Dtsch Dermatol Ges 12:1102–1106

    PubMed  Google Scholar 

  10. Kaufmann RA, Oberholzer PA, Cazzaniga S (2016) Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients. Eur J Dermatol 26:265–270

    PubMed  Google Scholar 

  11. Iannacone MR, Sinnya S, Pandeya N (2016) Prevalence of skin cancer and related skin tumors in high-risk kidney and liver transplant recipients in Queensland, Australia. J Invest Dermatol 136:1382–1386

    Article  CAS  PubMed  Google Scholar 

  12. Ulrich C, Schmook T, Nindl I et al (2003) Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol 149(Suppl 2):40–42

    Article  PubMed  Google Scholar 

  13. Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65:263–279

    Article  PubMed  Google Scholar 

  14. Costa C, Scalvenzi M, Ayala F (2015) How to treat actinic keratosis? An update. J Dermatol Case Rep 9:29–35

    Article  PubMed  PubMed Central  Google Scholar 

  15. Marks R, Foley P, Goodman G et al (1986) Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 115:649–655

    Article  CAS  PubMed  Google Scholar 

  16. Dodson JM, DeSpain J, Hewett JE et al (1991) Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 127:1029–1031

    Article  CAS  PubMed  Google Scholar 

  17. Fuchs A, Marmur E (2007) The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 33:1099–1101

    CAS  PubMed  Google Scholar 

  18. Röwert-Huber J, Patel MJ, Forschner T et al (2007) Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 156(Suppl 3):8–12

    Article  PubMed  Google Scholar 

  19. Fernandez-Figueras MT, Carrato C, Saenz X et al (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 29:991–997

    Article  CAS  PubMed  Google Scholar 

  20. Hensen P, Müller ML, Haschemi R et al (2009) Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol 19:345–354

    PubMed  Google Scholar 

  21. Babilas P, Landthaler M, Szeimies RM (2003) Aktinische Keratosen. Hautarzt 546:551–562

    Google Scholar 

  22. Luo JL, Tong WM, Yoon JH et al (2001) UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res 61(22):8158–8163

    CAS  PubMed  Google Scholar 

  23. Tomas D (2009) Apoptosis, UV-radiation, precancerosis and skin tumors. Acta Med Croatica 63(Suppl 2):53–58

    PubMed  Google Scholar 

  24. Kivisaari A, Kähäri VM (2013) Squamous cell carcinoma of the skin: emerging need for novel biomarkers. World J Clin Oncol 4:85–90

    Article  PubMed  PubMed Central  Google Scholar 

  25. Pierceall WE, Goldberg LH, Tainsky MA et al (1991) Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 4:196–202

    Article  CAS  PubMed  Google Scholar 

  26. Ratushny V, Gober MD, Hick R et al (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122:464–472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Spencer JM, Kahn SM, Jiang W et al (1995) Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 131:796–800

    Article  CAS  PubMed  Google Scholar 

  28. Bamford S, Dawson E, Forbes S et al (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91:355–358

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Riihilä PM, Nissinen LM, Farshchian M (2015) Complement factor I promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol 135:579–588

    Article  PubMed  Google Scholar 

  30. Lee CS, Bhaduri A, Mah A et al (2014) Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. Nat Genet 46:1060–1062

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Nicolas M et al (2003) Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33:416–421

    Article  CAS  PubMed  Google Scholar 

  32. Martincorena I, Roshan A, Gerstung M (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348(6237):880–886

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Hu B, Castillo E, Harewood L et al (2012) Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 149:1207–1220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Procopio MG, Csaba L, Al Labban D et al (2015) Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol 17:1193–1204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Accardi R, Gheit T (2014) Cutaneous HPV and skin cancer. Presse Med 43:435–443

    Article  Google Scholar 

  36. Asgari MM, Kiviat NB, Critchlow CW et al (2008) Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 128:1409–1417

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wang J, Aldabagh B, Yu J et al (2014) Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis. J Am Acad Dermatol 70:621–629

    Article  PubMed  PubMed Central  Google Scholar 

  38. Krutmann J, Berking C, Berneburg M et al (2015) New strategies in the prevention of actinic keratosis: a critical review. Skin Pharmacol Physiol 28:281–289

    Article  CAS  PubMed  Google Scholar 

  39. Bens G (2014) Sunscreens. Adv Exp Med Biol 810:429–463

    PubMed  Google Scholar 

  40. Ulrich C, Jürgensen JS, Degen A et al (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161(Suppl 3):78–84

    Article  PubMed  Google Scholar 

  41. Andrews MD (2004) Cryosurgery for common skin conditions. Am Fam Physician 69:2365–2372

    PubMed  Google Scholar 

  42. Kasuya A, Ohta I, Tokura Y et al (2015) Structural and immunological effects of skin cryoablation in a mouse model. PLOS ONE 10:e0123906

    Article  PubMed  PubMed Central  Google Scholar 

  43. Nashan D, Meiss F, Müller M (2013) Therapeutic strategies for actinic keratoses – a systematic review. Eur J Dermatol 23:14–32

    CAS  PubMed  Google Scholar 

  44. Zouboulis CC, Röhrs H (2005) Kryochirurgische Behandlung aktinischer Keratosen mit evidenzbasierter Übersicht. Hautarzt 56:353–358

    Article  CAS  PubMed  Google Scholar 

  45. Thai KE, Fergin P, Freeman M (2004) A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 43:687–692

    Article  PubMed  Google Scholar 

  46. Oliveira MC (2015) Histopathological analysis of the therapeutic response to cryotherapy with liquid nitrogen in patients with multiple actinic keratosis. An Bras Dermatol 90:384–389

    Article  PubMed  PubMed Central  Google Scholar 

  47. Kaufmann R, Spelman L, Weightman W et al (2008) Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 158:994–999

    Article  CAS  PubMed  Google Scholar 

  48. Szeimies RM, Karrer S, Radakovic-Fijan S et al (2002) Photodynamic therapy using topical methyl 5‑aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 47:258–262

    Article  CAS  PubMed  Google Scholar 

  49. Övermark M, Koskenmies S, Pitkänen S (2016) A retrospective study of treatment of squamous cell carcinoma in situ. Acta Derm Venereol 96:64–67

    Article  PubMed  Google Scholar 

  50. de Vries K, Prens EP (2015) Laser treatment and its implications for photodamaged skin and actinic keratosis. Curr Probl Dermatol 46:129–135

    Article  PubMed  Google Scholar 

  51. Wollina U, Konrad H, Karamfilov T (2001) Treatment of common warts and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 3:63–66

    Article  CAS  PubMed  Google Scholar 

  52. Ostertag JU, Quaedvlieg PJ, Neumann MH et al (2006) Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol Surg 32:261–267

    CAS  PubMed  Google Scholar 

  53. Stockfleth E, Kerl H, Zwingers T et al (2011) Low-dose 5‑fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165:1101–1108

    Article  CAS  PubMed  Google Scholar 

  54. Nguyen HP, Rivers JK (2016) Actikerall™ (5-Fluorouracil 0.5 % and Salicylic Acid 10 %) topical solution for patient-directed treatment of actinic keratoses. Skin Therapy Lett 31:1–3

    Google Scholar 

  55. Malvehy J, Alarcon I, Montoya J (2016) Treatment monitoring of 0.5 % 5‑fluorouracil and 10 % salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol 30:258–265

    Article  CAS  PubMed  Google Scholar 

  56. Szeimies RM, Dirschka T, Prechtl A et al (2015) Efficacy of low-dose 5‑fluorouracil/salicylic acid in actinic keratoses in relation to treatment duration. J Dtsch Dermatol Ges 13:430–438

    PubMed  Google Scholar 

  57. Hauschild A, Stockfleth E, Popp G et al (2009) Optimization of photodynamic therapy with a novel self-adhesive 5‑aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 160:1066–1074

    Article  CAS  PubMed  Google Scholar 

  58. Szeimies RM, Stockfleth E, Popp G et al (2010) Long-term follow-up of photodynamic therapy with a self-adhesive 5‑aminolaevulinic acid patch: 12 months data. Br J Dermatol 162:410–414

    Article  CAS  PubMed  Google Scholar 

  59. Vegter S, Tolley K (2014) A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLOS ONE 9:e96829

    Article  PubMed  PubMed Central  Google Scholar 

  60. Iraji F, Siadat AH, Asilian A et al (2008) The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf 7:167–172

    Article  CAS  PubMed  Google Scholar 

  61. Malvehy J, Roldán-Marín R, Iglesias-García P (2015) Monitoring treatment of field cancerisation with 3 % diclofenac sodium 2.5 % hyaluronic acid by reflectance confocal microscopy: a histologic correlation. Acta Derm Venereol 95:45–50

    Article  CAS  PubMed  Google Scholar 

  62. Pflugfelder A, Welter AK, Leiter U (2012) Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3 % diclofenac in 2.5 % hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 26:48–53

    Article  CAS  PubMed  Google Scholar 

  63. Shergill B, Zokaie S, Carr AJ (2013) Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 8:35–41

    PubMed  PubMed Central  Google Scholar 

  64. Lebwohl M, Swanson N, Anderson LL et al (2012) Ingenol mebutate gel for actinic keratosis. N Engl J Med 11:1010–1019

    Article  Google Scholar 

  65. Garbe C, Basset-Seguin N, Poulin Y et al (2016) Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a randomized, controlled 12-month study. Br J Dermatol 3:505–513

    Article  Google Scholar 

  66. Lebwohl M, Shumack S, Stein Gold L et al (2013) Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 1479:666–670

    Article  Google Scholar 

  67. Samorano LP, Torezan LA, Sanches JA (2015) Evaluation of the tolerability and safety of a 0.015 % ingenol mebutate gel compared to 5 % 5‑fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol 29:1822–1827

    Article  CAS  PubMed  Google Scholar 

  68. Augustin M, Tu JH, Knudsen KM (2015) Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol 72:816–821

    Article  CAS  PubMed  Google Scholar 

  69. Loven K, Stein L, Furst K et al (2002) Evaluation of the efficacy and tolerability of 0.5 % fluorouracil cream and 5 % fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24:990–1000

    Article  CAS  PubMed  Google Scholar 

  70. Pomerantz H, Hogan D, Eilers D et al (2015) Long-term efficacy of topical fluorouracil cream, 5 %, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 151:952–960

    Article  PubMed  Google Scholar 

  71. Krawtchenko N, Röwert-Huber J, Ulrich M et al (2007) A randomised study of topical 5 % imiquimod vs. topical 5‑fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1‑year follow-up. Br J Dermatol 157:34–40

    Article  CAS  PubMed  Google Scholar 

  72. Hanke CW, Beer KR, Stockfleth E et al (2010) Imiquimod 2.5 % and 3.75 % for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3‑week cycles. J Am Acad Dermatol 62:573–581

    Article  CAS  PubMed  Google Scholar 

  73. Stockfleth E, Sibbring GC, Alarcon I (2016) New topical treatment options for actinic keratosis: a systematic review. Acta Derm Venereol 96:17–22

    Article  CAS  PubMed  Google Scholar 

  74. Korman N, Moy R, Ling M et al (2005) Dosing with 5 % imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141:467–473

    Article  CAS  PubMed  Google Scholar 

  75. Santos-Juanes J, Esteve A, Mas-Vidal A et al (2011) Acute renal failure caused by imiquimod 5 % cream in a renal transplant patient: review of the literature on side effects of imiquimod. Dermatology 222:109–112

    Article  CAS  PubMed  Google Scholar 

  76. Szeimies RM, Karrer S, Bäcker H (2005) Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma. Hautarzt 56:430–440

    Article  PubMed  Google Scholar 

  77. Szeimies RM (2015) A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. J Eur Acad Dermatol Venereol. doi:10.1111/jdv.13206

    Google Scholar 

  78. Dirschka T, Radny P, Dominicus R et al (2013) Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 168:825–836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Wiegell SR (2015) Update on photodynamic treatment for actinic keratosis. Curr Probl Dermatol 46:122–128

    Article  PubMed  Google Scholar 

  80. Szeimies RM, Torezan L, Niwa A et al (2012) Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 167:150–159

    Article  CAS  PubMed  Google Scholar 

  81. Wiegell SR, Haedersdal M, Philipsen PA et al (2008) Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 158:740–746

    Article  CAS  PubMed  Google Scholar 

  82. Wiegell SR, Wulf HC, Szeimies RM et al (2012) Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 26:673–679

    Article  CAS  PubMed  Google Scholar 

  83. Lacour JP, Ulrich C, Gilaberte Y et al (2015) Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol 29:2342–2348

    Article  CAS  PubMed  Google Scholar 

  84. Fargnoli MC, Piccioni A, Neri L et al (2015) Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. J Eur Acad Dermatol Venereol 29:1926–1932

    Article  CAS  PubMed  Google Scholar 

  85. Szeimies RM, Lischner S, Philipp-Dormston W et al (2013) Photodynamic therapy for skin rejuvenation: treatment options - results of a consensus conference of an expert group for aesthetic photodynamic therapy. J Dtsch Dermatol Ges 11:632–636

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Behandlungszentrum Knappschaftskrankenhaus Recklinghausen, Klinik für Dermatologie und Allergologie, Klinikum VEST GmbH, Dorstener Str. 151, 45657, Recklinghausen, Deutschland

    T. Hommel & R.-M. Szeimies

Authors
  1. T. Hommel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R.-M. Szeimies
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Hommel.

Ethics declarations

Interessenkonflikt

T. Hommel hat als Prüfärztin an klinischen Studien im Indikationsgebiet der Firmen Almirall, Biofrontera, Galderma und Leo teilgenommen sowie Vortrags- und Beratungshonorare von Biofrontera und Galderma erhalten. R.-M. Szeimies hat als Prüfarzt an klinischen Studien im Indikationsgebiet der Firmen Almirall, Biofrontera, Galderma und Leo teilgenommen, von den genannten Firmen sowie photonamic Vortrags- und Beraterhonorare erhalten und ist Mitglied in Advisory Boards von Almirall, Biofrontera, Galderma, ISDIN, Leo, photonamic und Pierre-Fabre. Er war ferner an der Entwicklung eines ALA-haltigen transdermalen therapeutischen Systems (TTS) und einer LED-Lampe zur PDT beteiligt.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hommel, T., Szeimies, RM. Aktinische Keratosen. Hautarzt 67, 867–875 (2016). https://doi.org/10.1007/s00105-016-3873-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-016-3873-4

Schlüsselwörter

Keywords

Search

Navigation